Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study Read more about Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
Xencor Reports Third Quarter 2022 Financial Results Read more about Xencor Reports Third Quarter 2022 Financial Results
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting Read more about Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022 Read more about Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting Read more about Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
Xencor Appoints Nancy Valente, M.D., to Board of Directors Read more about Xencor Appoints Nancy Valente, M.D., to Board of Directors
Xencor Reports Second Quarter 2022 Financial Results Read more about Xencor Reports Second Quarter 2022 Financial Results
Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies Read more about Caris Life Sciences and Xencor Enter Target Discovery Collaboration and License Agreement for Novel XmAb® Bispecific Antibodies
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022 Read more about Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
